Clinical Trials
Early University of Calgary trial tests high-dose niacin as add-on treatment for glioblastoma
Imeripotiwa na AI Picha iliyoundwa na AI Imethibitishwa ukweli
Researchers at the University of Calgary are studying whether high doses of vitamin B3 (niacin) can improve outcomes for patients with newly diagnosed glioblastoma when added to standard treatment. An interim analysis of 24 patients found a higher-than-expected six‑month progression‑free survival rate, though investigators stress the results are preliminary and require ongoing safety monitoring.
A new experimental oral medication called elecoglipron improved blood sugar control and promoted weight loss in adults with type 2 diabetes during a phase 2b trial. Results from the SOLSTICE study were presented at the American Diabetes Association's Scientific Sessions and published in The Lancet.
Imeripotiwa na AI
A new treatment called Daraxonrasib has shown strong results against advanced pancreatic cancer in a recent clinical trial. The drug targets a genetic mutation long considered impossible to treat effectively.
Takeda Pharmaceutical has announced that its AI-assisted oral psoriasis drug zasocitinib proved safe and effective in late-stage trials. The once-daily pill outperformed placebo and the existing therapy apremilast in clearing skin for patients with moderate-to-severe plaque psoriasis. If approved, it would mark one of the first drugs discovered with artificial intelligence.
Imeripotiwa na AI
An experimental nasal vaccine has for the first time prevented the colonization of whooping cough bacteria in humans, according to a recently published clinical trial. This breakthrough could curb the disease's spread, particularly in a year of record cases in England. The BPZE1 vaccine, developed by ILiAD Biotechnologies, reduced bacterial presence by over 97% compared to placebo.
A combination of enzalutamide and hormone therapy has reduced the risk of death by more than 40% in men with recurring prostate cancer, according to a major clinical trial. The study, involving over 1,000 patients worldwide, was led by researchers at Cedars-Sinai and presented at a medical congress in Berlin. Experts describe the findings as a game changer for treating aggressive cases.
Imeripotiwa na AI
The U.S. Food and Drug Administration has finalized a rule requiring drug sponsors to submit diversity action plans for clinical trials. This aims to ensure better representation of underrepresented groups in medical research. The rule takes effect in 2025.
Virus injection halts pancreatic tumor growth in trial
Alhamisi, 28. Mwezi wa tano 2026, 16:21:52Gene-editing drug slashes bad cholesterol 62 percent in trial
Jumatatu, 25. Mwezi wa tano 2026, 16:39:34Study finds beta blockers offer no benefit after uncomplicated heart attacks
Jumapili, 17. Mwezi wa tano 2026, 08:37:15Tenaya Therapeutics publishes RIDGE-1 data on TN-401 gene therapy
Jumanne, 12. Mwezi wa tano 2026, 11:26:49Intellia reports strong phase iii results for hae treatment
Jumamosi, 22. Mwezi wa kumi na moja 2025, 02:26:34Stem cell therapy restores vision in AMD patients
Alhamisi, 13. Mwezi wa kumi na moja 2025, 04:09:10Cheap gout drug colchicine may prevent heart attacks and strokes
Alhamisi, 6. Mwezi wa kumi na moja 2025, 13:09:09Oral semaglutide pill yields up to 16.6% weight loss in NEJM obesity trial
Jumatano, 22. Mwezi wa kumi 2025, 20:00:24Wegovy provides heart benefits even with minimal weight loss
Jumatatu, 20. Mwezi wa kumi 2025, 00:10:21New compounds halt cancer growth without damaging healthy cells